CAJ | 학술논문

目的观察经导管肝动脉化疗栓塞(TACE)联合索拉非尼治疗中晚期肝细胞癌的有效性和安全性.方法 40例已接受过TACE治疗的中晚期肝细胞癌患者口服索拉非尼单药治疗,400mg,2次/d,直至病情进展或出现不可耐受的毒性反应.按照实体瘤疗效评价标准(RECIST)评价疗效,按照美国国立癌症研究所常见毒性事件标准(NCI-CTCAE)评价不良反应.结果 40例中晚期肝细胞癌患者中,获得完全缓解1例,部分缓解7例,疾病稳定19例,疾病进展13例,疾病控制率为67.5%.全组患者的生存时间为1～18个月,1年生存率为54.0%.主要不良反应为手足皮肤反应,其次是腹泻和血小板计数降低.结论 TACE联合索拉非尼治疗中晚期肝细胞癌是有效和安全的.
목적 관찰경도관간동맥화료전새(TACE)연합색랍비니치료중만기간세포암적유효성화안전성.방법 40례이접수과TACE치료적중만기간세포암환자구복색랍비니단약치료,400mg,2차/d,직지병정진전혹출현불가내수적독성반응.안조실체류료효평개표준(RECIST)평개료효,안조미국국립암증연구소상견독성사건표준(NCI-CTCAE)평개불량반응.결과 40례중만기간세포암환자중,획득완전완해1례,부분완해7례,질병은정19례,질병진전13례,질병공제솔위67.5%.전조환자적생존시간위1～18개월,1년생존솔위54.0%.주요불량반응위수족피부반응,기차시복사화혈소판계수강저.결론 TACE연합색랍비니치료중만기간세포암시유효화안전적.
Objective To observe the efficacy and side effects of transarterial chemoembolization (TACE) combined with sorafenib for advanced hepatocellular carcinoma (HCC). Methods Forty patients with HCC were treated with sorafenib (400 mg bid) after TACE. The efficacy was evaluated according to RECIST 1. 1 criteria, and side effects were assessed by NCI CTC 3.0 criteria. Results Among the forty cases, one case achieved complete remission (CR), seven cases achieved partial remission (PR) , nineteen cases achieved stable disease (SD) and thirteen cases had progressive disease (PD). The disease control rate (DCR) was 67.5%. The overall survival time was 1-18 months, and 1 -year survival rate was 54.0%.The major adverse events were hand-foot skin reaction, diarrhea and thrombocytopenia. Conclusion The combined therapy of TACE and sorafenib is effective and well tolerated for advanced HCC.